17
Views
1
CrossRef citations to date
0
Altmetric
Review

Future anti-inflammatory metabolic and cardiovascular management of Type 2 diabetes mellitus

Pages 1683-1689 | Published online: 02 Mar 2005

Bibliography

  • LAIGHT DW: Therapeutic approaches to the management of dysmetabolic cardiovascular disease. Expert Opin. Then Patents (2002) 12:615–620.
  • GURNELL M, SAVAGE DB, CHATTERJEE KK et al.: The metabolic syndrome: peroxisome proliferator-activated receptor-7 and its therapeutic modulation. j Clin. Endocrinol Metab. (2003) 88:2412–2421.
  • LAIGHT DW, CARRIER MJ, ANGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. (2000) 47:457–464.
  • LAIGHT DW, CARRIER MJ, ANGGARD EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev. (1999) 15:274–282.
  • SOWERS JR: Update on the cardiometabolic syndrome. Diabetes (2001) 4:17–23.
  • ABATE N: Obesity and cardiovascular disease. Pathogenic role of the metabolic syndrome and therapeutic implications. 1. Diabetes Comp. (2000) 14:154–174.
  • HAFFNER SM: The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. " Diabetes Comp. (1997) 11:69–76.
  • MARKS JB, RASKIN P: Cardiovascular risk in diabetes - a brief review.' Diabetes Comp. (2000) 14:108–115.
  • HAFFNER SM: Prediabetes, insulin resistance, inflammation and CVD risk. Diabetes Res. Clin. Pract. (2003) 61:S9–S18.
  • DANDONA P, ALJADA A, CHAUDHURI A, BANDYOPADHYAY A: The potential influence of inflammation and insulin on the pathogenesis and treatment of atheroslcerosis-related complications in Type 2 diabetes. " Clin. Endocrinol Metab. (2003) 88:2422–2429.
  • WILDS, BYRNE C: Prevention of Type 2 diabetes and associated cardiovascular disease. Cardiabetes (2001) 1:20–25.
  • NO AUTHORS LISTED: Effects of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes mellitus (UK Prospective Diabetes Study (UKPDS) group 34). Lancet (1998) 356:854–865.
  • LAIGHT DW: Therapeutic approaches to insulin resistance. Expert Opin. Then Patents (2000) 10:1703–1709.
  • BIONDI-ZOCCAI GGL, ABBATE A, LIUZZO G et al.: Atherosclerosis, inflammation and diabetes. Am. J. Cardiol (2003) 41:1071–1077.
  • PLUTZKY J, VIBERTI G, HAFFNER S: Atherosclerosis in Type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. " Diabetes Comp. (2002) 16:401–415.
  • GREENBERG AS: The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in Type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. " Diabetes Comp. (2003) 17:218–228.
  • DAS UN: Is metabolic syndrome X an inflammatory condition? Exp. Biol. Med. (2002) 227:989–997.
  • DUNCAN BB, SCHMIDT MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med. J. (2001) 119:122–127.
  • SYED MA, BARINAS-MITCHELL E, PIETROPAOLO SL et al.: Is Type 2 diabetes a chronic inflammatory/autoimmune disease? Diab. Num. Metab. (2002) 15:68–83.
  • PICKUP JC, CROOK MA: Is Type II diabetes mellitus a disease of the innate immune system? Diabetologia (1998) 41:1241–1248.
  • HAYDEN JM, REAVEN PD: Cardiovascular disease in diabetes mellitus Type 2: a potential role for novel cardiovascular risk factors. Curt: Opin. Lipidol (2000) 11:519–528.
  • THORAND B, LOWEL H, SCHNEIDER A et al.: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch. Intern. Med. (2003) 163:93–99.
  • CHAN JC, CHEUNG JC, STEHOUWER CD et al.: The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modelling. Int. J. Obesity(2002) 26:994–1008.
  • PRADHAN AD, RIDKER PM: Do atheroslcerosis and Type 2 diabetes share a common inflammatory basis? Eur: Heart J. (2002) 23:831–834.
  • STEHOUWER CD, GALL MA, TWISK JW et al.: Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in Type 2 diabetes. Diabetes (2002) 51:1157–1165.
  • SHURTZ-SWIRSKI R, SELA S, HERSKOVITS AT et al.: Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in Type 2 diabetic patients. Diabetes Care (2001) 24:104–110.
  • LINDSAY RS, KRAKOFF J, HANSON RL, BENNETT PH, KNOWLER WC: 7-globulin levels predict Type 2 diabetes in the Pima Indian population. Diabetes (2001) 50: 1598-1603.
  • VOZAROVA B, WEYER C, LINDSAY RS, PRATLEY RE, BOGARDUS C, TATARANNI PA: High white cell count is associated with worsening of insulin sensitivity and predicts development of Type 2 diabetes. Diabetes (2002) 51:455–461.
  • FESTA A, D'AGOSTINO R, TRACY RP et al.: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes. Diabetes (2002) 51:1131–1137.
  • LEINONEN E, HURT-CAMEJO E, WIKLUND O, HULTEN LM, HIUKKA A, TASKINEN MR: Insulin resistance and adiposity correlate with acute-phase reaction and soluble adhesion molecules in Type 2 diabetes. Atherosclerosis (2003) 166:387–394.
  • RIDKER PM, BURING JE, COOK NR,RIFAI N: C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation (2003) 107:391–397.
  • ENGSTROM G, STAVENOW L, HEDBLAD B et al: Inflammation-sensitive plasma proteins, diabetes and mortality and incidence of myocardial infarction and stroke. Diabetes (2003) 52:442–447.
  • DESSEIN PH, JOFFE BI, STANWIX AE: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. (2002) 4:R12.
  • DAS UN: Is obesity an inflammatory condition? Nutrition (2001) 17:953–966.
  • GRIMBLE RF: Inflammatory status and insulin resistance. Carr: Opin. Clin. Nutr: Metab. Care (2002) 5:551–559.
  • BEHRENDT D, GANZ P: Endothelial function: from vascular biology to clinical applications. Am. Cardiol (2002) 90:40L–48L.
  • VICENT D, IILANY J, KONDO T et al: The role of endothelial cell signalling in the regulation of vascular tone and insulin resistance. I Clin. Invest. (2003) 111:1373–1380.
  • LI X, KOLLTVEIT KM, TRONSTAD L, OLSEN I: Systemic diseases caused by oral infection. Clin. Microbial. Rev. (2000) 13:547–558.
  • GLURICH I, GROSSI S, ALBINI B et al.: Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin. Diagnostic Lab. Immunol (2002) 9:425–432.
  • GROSSI SG, GENCO RJ: Periodontal disease and diabetes mellitus: a two-way relationship. Ann. Periodontol (1998) 3:51–61.
  • ALJADA A: Endothelium, inflammation and diabetes. Metab. Syndrome Rel. Disorders (2003) 1:3–21.
  • ROSENSON RS, KONIG W: Utility of inflammatory markers in the management of coronary artery disease. Am. Cardiol (2003) 92:10i–18i.
  • HUNDAL RS, PETERSEN KF, MAYERSON AB et al.: Mechanism by which high-dose aspirin improves glucose metabolism in Type 2 diabetes. Clin. Invest. (2002) 109:1321–1326.
  • KIM JK, YOON-JUNG K, FILLMORE JJ et al.: Prevention of fat-induced insulin resistance by salicylate. Clin. Invest. (2001) 108:437–446.
  • MANCINI GBJ: Emerging role of angiotensin II Type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Can. J. Cardiol (2002) 18:1309–1316.
  • HOLM T, ANDREASSEN AK, UELAND T et al.: Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol (2001) 87:815–818.
  • BRASIER AR, RECINOS A III, ELEDRISI MS: Vascular inflammation and the renin-angiotensin system. Arteriosclec Thromb. Vase. Biol. (2002) 22:1257–1266.
  • MAGSINO CH, HAM OUDA W, BAPNA V et al.: Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am. Cardiol (2000) 86:443–448.
  • DANDONA P, KUMAR V, ALJADA A et al.: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor lcB, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J. Clin. Endocrinol Metab. (2003) 88:4496–4501.
  • DANDONA P, KARNE R, GHANIM H, HAM OUDA W, ALJADA A, MAGSINO CH Jr: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation (2000) 101:122–124.
  • MIKKOLA TS, CLARKSON TB: Oestrogen replacement therapy, atherosclerosis and vascular function. Cardiovasc. Res. (2002) 53:605–619.
  • MAGSINO CH Jr, HAMOUDA W, GHANIM H, BROWNE R, ALJADA A, DANDONA P: Effect of triiodothyronine on reactive oxygen species generation by leukocytes, indices of oxidative damage and antioxidant reserve. Metabolism (2000) 49:799–803.
  • LAIGHT DW: Nitric oxide therapy for cardiovascular disease. Expert Opin. Then Patents (2001) 11:999–1005.
  • VIBERTI GC: Rosiglitazone: potential beneficial impact on cardiovascular disease. Int. I Clin. Pract. (2003) 57:128–134.
  • FRUCHART JC, STAELS B, DURIEZ P: PPARS, metabolic disease and atheroslcerosis. Pharmacol Res. (2001) 44:345–352.
  • GHANIM H, GARG R, ALJADA A et al.: Suppression of nuclear factor-KB and stimulation of inhibitor lcB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherogenic effect in the obese. Clin. Endocrinol Metab. (2001) 86:1306–1312.
  • ZIMMET P: Addressing the insulin resistance syndrome - a role for thiazolidinediones. Trends Cardiovasc. Med. (2002) 12:354–362.
  • WAKINO S, LAW RE, HSUEH WA: Vascular protective effects by activation of nuclear receptor PPARy. Diabetes Comp. (2002) 16:46–49.
  • RAM VI: Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. Frog. Drug Res. (2003) 60:94–132.
  • ASNANI S, THEUMA P, FONSECA VA: PPARy agonists and vascular risk factors: potential effects on cardiovascular disease. Metab. Syndrome Rel. Disorders (2003) 1:23–53.
  • LEBOVITZ HE: Rationale for and role of thiazolidinediones in Type 2 diabetes mellitus. Am. J. Cardiol (2002) 90:34G–41G.
  • MARTENS FM, VISSEREN FL, LEMAY J et al.: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463–1480.
  • OMI H, OKAYAMA N, SHIMIZU M et al.: Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells- effect of antidiabetic medicines. Diabetes Comp. (2002) 16:201–208.
  • DANDONA P, ALJADA A: A rational approach to pathogenesis and treatment of Type 2 diabetes mellitus, insulin resistance, inflammation and atheroslcerosis. Am. Cardiol. (2002) 90:27G–33G.
  • DANDONA P, ALJADA A, MOHANTY P et at Insulin inhibits intranuclear nuclear factor lcB and stimulates IlcB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? Clin. Endocrinol. Metab. (2001) 86:3257–3265.
  • BARZILAYJI, FREEDLAND ES: Inflammation and its relationship to insulin resistance, Type 2 diabetes mellitus and endothelial dysfunction. Metab. Syndrome Rel. Disorders. (2003) 1:55–67.
  • SCOTT CL: Diagnosis, prevention and intervention for the metabolic syndrome. Am. Cardiol (2003) 92:35i–42i.
  • KONIG W: Insulin resistance, heart disease and inflammation. Int. Clin. Pharmacol (2002) S132:23–31.
  • MCFARLANE SI, KUMAR A, SOWERS JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am.j Cardiol. (2003) 91:30H–37H.
  • FREEMAN DJ, NORRIE J, SATTAR N et al.: Pravastatin and the development of diabetes mellitus. Circulation (2001) 103:357–362.
  • SOWERS JR: Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol (2003) 91:14B–22B.
  • BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic I3-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes (2002) 51:2796–2803.
  • CAMPBELL IW: Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in Type 2 diabetes mellitus? Drugs (2000) 60:1017–1028.
  • GUNNETT CA, HEISTAD DD, FARACI FM: Interleukin-10 protects nitric oxide-dependent relaxation during diabetes. Diabetes (2002) 51: 1931-1937.
  • ASADULLAH K, STERRY W, VOLK HD:Interleukin-10 therapy - a new approach. Pharmacol Rev (2003) 55:241–269.
  • NISHIMURA F, MURAYAMA Y: Periodontal inflammation and insulin resistance - lessons from obesity. J. Dent. Res. (2001) 80:1690–1694.
  • STIER CT Jr: Eplerenone: a selective aldosterone blocker. Cardiovasc. Drug Rev (2003) 21:169–184.
  • LAIGHT DW, DESAI KM, GOPAUL NK, ANGGARD EE, CARRIER MJ: Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br: J. Pharmacol (1999) 128:269–271.
  • LAIGHT DW: Organic nitrate-induced oxidant stress and cardiovascular therapy. Expert Opin. Then Patents (2003) 13:1–6.
  • http://www.update-software.com BELCH JJF: The Prevention Of Progression of Asymptomatic Diabetic Arterial Desease (POPADAD) study, a multicentre study. Accessed 27 August 2003. The goal of this study was to determine whether or not aspirin and antioxidant therapy can reduce the incidence of vascular events in diabetic individuals.
  • http://www.update-software.com DAVID M: DREAM trial: diabetes reduction assessment with ramipril and rosiglitazone medication trial. Accessed 27 August 2003. The goal of this study was to determine whether ramipril or rosiglitazone reduces incident diabetes in subjects at risk.
  • www.update-software.com JOHNSTON D: Rosiglitazone and plaque study: a 12-month randomised, double-blind, placebo-controlled, magnetic resonance imaging study to evaluate the subjects with T2DM and co-existing vascular disease or hypertension. Accessed 27 August 2003. The goal of this study was to examine the effect of rosiglitazone on carotid atheroma and cardiovascular risk factors in T2DM.
  • http://www.update-software.com PAGE MD: PROATIVE: prospective pioglitazone clinical trial in macrovascular events. Accessed 27 August 2003. The goal of this study was to demonstrate that pioglitazone reduces mortality and macrovascular morbidity in high-risk patients with T2DM.
  • http://www.update-software.com MACLAREN N: A clinical trial to prevent the complications of insulin resistance (including Type 2 diabetes). Accessed 27 August 2003. The goal of this study was to treat emergent insulin resistance and clinical manifestations in childhood and prevent progression to T2DM. Interventions include metformin plus pioglitazone or rosiglitazone.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.